

# John P Overington

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5200191/publications.pdf>

Version: 2024-02-01

106  
papers

22,017  
citations

50170

46  
h-index

30848

102  
g-index

111  
all docs

111  
docs citations

111  
times ranked

28761  
citing authors

#	ARTICLE	IF	CITATIONS
1	How many drug targets are there?. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 993-996.	21.5	3,073
2	ChEMBL: a large-scale bioactivity database for drug discovery. <i>Nucleic Acids Research</i> , 2012, 40, D1100-D1107.	6.5	3,028
3	The ChEMBL database in 2017. <i>Nucleic Acids Research</i> , 2017, 45, D945-D954.	6.5	1,718
4	A comprehensive map of molecular drug targets. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 19-34.	21.5	1,608
5	The ChEMBL bioactivity database: an update. <i>Nucleic Acids Research</i> , 2014, 42, D1083-D1090.	6.5	1,283
6	An atlas of genetic influences on human blood metabolites. <i>Nature Genetics</i> , 2014, 46, 543-550.	9.4	1,084
7	The genome of the blood fluke <i>Schistosoma mansoni</i> . <i>Nature</i> , 2009, 460, 352-358.	13.7	945
8	The promise and peril of chemical probes. <i>Nature Chemical Biology</i> , 2015, 11, 536-541.	3.9	698
9	X-ray analysis of HIV-1 proteinase at 2.7 Å... resolution confirms structural homology among retroviral enzymes. <i>Nature</i> , 1989, 342, 299-302.	13.7	477
10	Can we rationally design promiscuous drugs?. <i>Current Opinion in Structural Biology</i> , 2006, 16, 127-136.	2.6	472
11	HOMSTRAD: A database of protein structure alignments for homologous families. <i>Protein Science</i> , 1998, 7, 2469-2471.	3.1	461
12	ChEMBL web services: streamlining access to drug discovery data and utilities. <i>Nucleic Acids Research</i> , 2015, 43, W612-W620.	6.5	437
13	The druggable genome and support for target identification and validation in drug development. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	437
14	Probing the links between in vitro potency, ADMET and physicochemical parameters. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 197-208.	21.5	409
15	JOY: protein sequence-structure representation and analysis. <i>Bioinformatics</i> , 1998, 14, 617-623.	1.8	384
16	Comprehensive characterization of the Published Kinase Inhibitor Set. <i>Nature Biotechnology</i> , 2016, 34, 95-103.	9.4	289
17	A Structural Basis for Sequence Comparisons. <i>Journal of Molecular Biology</i> , 1993, 233, 716-738.	2.0	286
18	Genomic-scale prioritization of drug targets: the TDR Targets database. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 900-907.	21.5	282

#	ARTICLE	IF	CITATIONS
19	Derivation of rules for comparative protein modeling from a database of protein structure alignments. <i>Protein Science</i> , 1994, 3, 1582-1596.	3.1	275
20	PSICQUIC and PSISCORE: accessing and scoring molecular interactions. <i>Nature Methods</i> , 2011, 8, 528-529.	9.0	274
21	Unexplored therapeutic opportunities in the human genome. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 317-332.	21.5	263
22	Knowledge-based protein modelling and design. <i>FEBS Journal</i> , 1988, 172, 513-520.	0.2	236
23	Alignment and Searching for Common Protein Folds Using a Data Bank of Structural Templates. <i>Journal of Molecular Biology</i> , 1993, 231, 735-752.	2.0	174
24	SureChEMBL: a large-scale, chemically annotated patent document database. <i>Nucleic Acids Research</i> , 2016, 44, D1220-D1228.	6.5	156
25	From comparisons of protein sequences and structures to protein modelling and design. <i>Trends in Biochemical Sciences</i> , 1990, 15, 235-240.	3.7	149
26	Modeling $\alpha$ -helical transmembrane domains: The calculation and use of substitution tables for lipid-facing residues. <i>Protein Science</i> , 1993, 2, 55-70.	3.1	143
27	UniChem: a unified chemical structure cross-referencing and identifier tracking system. <i>Journal of Cheminformatics</i> , 2013, 5, 3.	2.8	133
28	Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. <i>Cell Chemical Biology</i> , 2018, 25, 224-229.e2.	2.5	124
29	Fragment Ranking in Modelling of Protein Structure. <i>Journal of Molecular Biology</i> , 1993, 229, 194-220.	2.0	119
30	Activity, assay and target data curation and quality in the ChEMBL database. <i>Journal of Computer-Aided Molecular Design</i> , 2015, 29, 885-896.	1.3	118
31	Improving the odds of drug development success through human genomics: modelling study. <i>Scientific Reports</i> , 2019, 9, 18911.	1.6	112
32	Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. <i>Drug Discovery Today</i> , 2010, 15, 804-811.	3.2	102
33	Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel. <i>Bioinformatics</i> , 2016, 32, 85-95.	1.8	95
34	PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2017, 4, CD011748.	1.5	93
35	Computational and Practical Aspects of Drug Repositioning. <i>Assay and Drug Development Technologies</i> , 2015, 13, 299-306.	0.6	89
36	Comparative modelling of major house dust mite allergen Der p I: structure validation using an extended environmental amino acid propensity table. <i>Protein Engineering, Design and Selection</i> , 1994, 7, 869-894.	1.0	82

#	ARTICLE	IF	CITATIONS
37	Minimum information about a bioactive entity (MIABE). <i>Nature Reviews Drug Discovery</i> , 2011, 10, 661-669.	21.5	80
38	Chemical, Target, and Bioactive Properties of Allosteric Modulation. <i>PLoS Computational Biology</i> , 2014, 10, e1003559.	1.5	75
39	Benchmarking of protein descriptor sets in proteochemometric modeling (part 2): modeling performance of 13 amino acid descriptor sets. <i>Journal of Cheminformatics</i> , 2013, 5, 42.	2.8	73
40	Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. <i>ACS Central Science</i> , 2016, 2, 687-701.	5.3	68
41	The prediction and orientation of $\alpha$ -helices from sequence alignments: the combined use of environment-dependent substitution tables, Fourier transform methods and helix capping rules. <i>Protein Engineering, Design and Selection</i> , 1994, 7, 645-653.	1.0	58
42	Antibody informatics for drug discovery. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 2002-2015.	1.1	58
43	Artificial intelligence, drug repurposing and peer review. <i>Nature Biotechnology</i> , 2020, 38, 1127-1131.	9.4	56
44	Molecular recognition in protein families: A database of aligned three-dimensional structures of related proteins. <i>Biochemical Society Transactions</i> , 1993, 21, 597-604.	1.6	53
45	Target Prediction for an Open Access Set of Compounds Active against <i>Mycobacterium tuberculosis</i> . <i>PLoS Computational Biology</i> , 2013, 9, e1003253.	1.5	51
46	Unprecedentedly Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound Kinase Activities: A Way toward Selective Promiscuity by Design?. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 1654-1675.	2.5	50
47	Nicastrin, a presenilin-interacting protein, contains an aminopeptidase/transferrin receptor superfamily domain. <i>Trends in Biochemical Sciences</i> , 2001, 26, 213-214.	3.7	49
48	[34] Discrimination of common protein folds: Application of protein structure to sequence/structure comparisons. <i>Methods in Enzymology</i> , 1996, 266, 575-598.	0.4	46
49	Chemical databases: curation or integration by user-defined equivalence?. <i>Drug Discovery Today: Technologies</i> , 2015, 14, 17-24.	4.0	43
50	Comparison of three-dimensional structures of homologous proteins. <i>Current Opinion in Structural Biology</i> , 1992, 2, 394-401.	2.6	42
51	The ChEMBL database: a taster for medicinal chemists. <i>Future Medicinal Chemistry</i> , 2014, 6, 361-364.	1.1	42
52	PDBLIG: A Classification of Small Molecular Protein Binding in the Protein Data Bank. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3807-3816.	2.9	41
53	Global Analysis of Small Molecule Binding to Related Protein Targets. <i>PLoS Computational Biology</i> , 2012, 8, e1002333.	1.5	41
54	Mycobacterial Dihydrofolate Reductase Inhibitors Identified Using Chemogenomic Methods and In Vitro Validation. <i>PLoS ONE</i> , 2015, 10, e0121492.	1.1	40

#	ARTICLE	IF	CITATIONS
55	diXa: a data infrastructure for chemical safety assessment. <i>Bioinformatics</i> , 2015, 31, 1505-1507.	1.8	40
56	The relationship between target-class and the physicochemical properties of antibacterial drugs. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5218-5224.	1.4	40
57	Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery. <i>PLoS ONE</i> , 2015, 10, e0142293.	1.1	38
58	Synthesis of Macrocyclic, Potential Protease Inhibitors Using a Generic Scaffold. <i>Journal of Organic Chemistry</i> , 2002, 67, 4882-4892.	1.7	33
59	Structural and Functional View of Polypharmacology. <i>Scientific Reports</i> , 2017, 7, 10102.	1.6	33
60	Collation and data-mining of literature bioactivity data for drug discovery. <i>Biochemical Society Transactions</i> , 2011, 39, 1365-1370.	1.6	31
61	Annotating Human P&Glycoprotein Bioassay Data. <i>Molecular Informatics</i> , 2012, 31, 599-609.	1.4	30
62	UniChem: extension of InChI-based compound mapping to salt, connectivity and stereochemistry layers. <i>Journal of Cheminformatics</i> , 2014, 6, 43.	2.8	28
63	A drug target slim: using gene ontology and gene ontology annotations to navigate protein-ligand target space in ChEMBL. <i>Journal of Biomedical Semantics</i> , 2016, 7, 59.	0.9	27
64	Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma. <i>Cancer Discovery</i> , 2022, 12, 416-431.	7.7	25
65	Design of Selective Thrombin Inhibitors Based on the (R)-Phe-Pro-Arg Sequence. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2432-2453.	2.9	22
66	Prioritizing the proteome: identifying pharmaceutically relevant targets. <i>Drug Discovery Today</i> , 2002, 7, 516-521.	3.2	22
67	Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach. <i>Frontiers in Pharmacology</i> , 2017, 8, 681.	1.6	22
68	Cheminformatics. <i>Communications of the ACM</i> , 2012, 55, 65-75.	3.3	21
69	Role of open chemical data in aiding drug discovery and design. <i>Future Medicinal Chemistry</i> , 2010, 2, 903-907.	1.1	20
70	The EBI enzyme portal. <i>Nucleic Acids Research</i> , 2013, 41, D773-D780.	6.5	19
71	Chemogenomics Approaches for Receptor Deorphanization and Extensions of the Chemogenomics Concept to Phenotypic Space. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1964-1977.	1.0	18
72	A ligand's-eye view of protein similarity. <i>Nature Methods</i> , 2013, 10, 116-117.	9.0	18

#	ARTICLE	IF	CITATIONS
73	myChEMBL: a virtual machine implementation of open data and cheminformatics tools. <i>Bioinformatics</i> , 2014, 30, 298-300.	1.8	18
74	A large-scale crop protection bioassay data set. <i>Scientific Data</i> , 2015, 2, 150032.	2.4	18
75	Identification of Allosteric Modulators of Metabotropic Glutamate 7 Receptor Using Proteochemometric Modeling. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 2976-2985.	2.5	18
76	Insights into protein function through large-scale computational analysis of sequence and structure. <i>Trends in Biotechnology</i> , 2001, 19, S61-S66.	4.9	17
77	Setting Our Sights on Infectious Diseases. <i>ACS Infectious Diseases</i> , 2020, 6, 3-13.	1.8	17
78	Insights into protein function through large-scale computational analysis of sequence and structure. <i>Trends in Biotechnology</i> , 2001, 19, 61-66.	4.9	16
79	Protein sequence analysis in silico: application of structure-based bioinformatics to genomic initiatives. <i>Current Opinion in Pharmacology</i> , 2002, 2, 574-580.	1.7	16
80	Scientific Lenses to Support Multiple Views over Linked Chemistry Data. <i>Lecture Notes in Computer Science</i> , 2014, , 98-113.	1.0	16
81	Rapid Analysis of Pharmacology for Infectious Diseases. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1292-1300.	1.0	15
82	Mapping small molecule binding data to structural domains. <i>BMC Bioinformatics</i> , 2012, 13, S11.	1.2	14
83	Classification and analysis of a large collection of in vivo bioassay descriptions. <i>PLoS Computational Biology</i> , 2017, 13, e1005641.	1.5	14
84	Open data for drug discovery: learning from the biological community. <i>Future Medicinal Chemistry</i> , 2012, 4, 1865-1867.	1.1	13
85	ADME SARfari: comparative genomics of drug metabolizing systems. <i>Bioinformatics</i> , 2015, 31, 1695-1697.	1.8	12
86	MyChEMBL: A Virtual Platform for Distributing Cheminformatics Tools and Open Data. <i>Challenges</i> , 2014, 5, 334-337.	0.9	11
87	A document classifier for medicinal chemistry publications trained on the ChEMBL corpus. <i>Journal of Cheminformatics</i> , 2014, 6, 40.	2.8	11
88	PPDMs—a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains. <i>Bioinformatics</i> , 2015, 31, 776-778.	1.8	11
89	Rational design of non-resistant targeted cancer therapies. <i>Scientific Reports</i> , 2017, 7, 46632.	1.6	11
90	Protein Three-Dimensional Structural Databases: Domains, Structurally Aligned Homologues and Superfamilies. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 1998, 54, 1168-1177.	2.5	6

#	ARTICLE	IF	CITATIONS
91	The functional therapeutic chemical classification system. <i>Bioinformatics</i> , 2014, 30, 876-883.	1.8	6
92	The Molecular Basis of Predicting Druggability. , 0, , 1315-1334.		5
93	Brain: biomedical knowledge manipulation. <i>Bioinformatics</i> , 2013, 29, 1238-1239.	1.8	5
94	Transporter assays and assay ontologies: useful tools for drug discovery. <i>Drug Discovery Today: Technologies</i> , 2014, 12, e47-e54.	4.0	4
95	Modelling of the lignin peroxidase LIII of <i>Phlebia radiata</i> : use of a sequence template generated from a 3-D structure. <i>Protein Engineering, Design and Selection</i> , 1993, 6, 177-182.	1.0	3
96	Chapter 28. Recent development in cheminformatics and chemogenomics. <i>Annual Reports in Medicinal Chemistry</i> , 2003, 38, 285-294.	0.5	3
97	Knowledge-Based Protein Modelling: Human Plasma Kallikrein and Human Neutrophil Defensin. , 1990, , 567-574.		3
98	Chapter 19. Expanding and exploring cellular pathways for novel drug targets. <i>Annual Reports in Medicinal Chemistry</i> , 2002, 37, 187-196.	0.5	2
99	Pleiotropic Effects of Statins. <i>Annual Reports in Medicinal Chemistry</i> , 2004, 39, 239-258.	0.5	2
100	ChEMBL Beaker: A Lightweight Web Framework Providing Robust and Extensible Cheminformatics Services. <i>Challenges</i> , 2014, 5, 444-449.	0.9	2
101	Towards predictive resistance models for agrochemicals by combining chemical and protein similarity via proteochemometric modelling. <i>Journal of Chemical Biology</i> , 2014, 7, 119-123.	2.2	2
102	Comparison of three-dimensional structures of homologous proteins. <i>Current Biology</i> , 1992, 2, 376.	1.8	1
103	The comparison of structures and sequences: alignment, searching and the detection of common folds. , 1994, , .		1
104	Symposium 1: Structure and engineering of proteins: New developments. <i>Fresenius' Journal of Analytical Chemistry</i> , 1990, 337, 1-3.	1.5	0
105	New open drug activity data at EBI. <i>Chemistry Central Journal</i> , 2009, 3, .	2.6	0
106	Knowledge-Based Protein Modeling and the Design of Novel Molecules. , 1990, , 209-227.		0